The application of PARP inhibition to our CLL models has highlighted the efficacy of this drug in del(11q) cells with biallelic inactivation of ATM in vitro, in vivo and ex vivo. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.